

Novel Dihydropyrimidinone Derivatives as Potential P-Glycoprotein Modulators

Sabera Bijani,[◆] Faraz Shaikh,[◆] Sheefa Mirza, Shirley Weng In Siu, Nayan Jain, Rakesh Rawal, Nigel G. J. Richards, Anamik Shah,^{*} and Ashish Radadiya^{*}



Cite This: *ACS Omega* 2022, 7, 16278–16287



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: P-glycoprotein (Pgp), an ATP binding cassette (ABC) transporter, is an ATP-dependent efflux pump responsible for cancer multidrug resistance. As part of efforts to identify human Pgp (hPgp) inhibitors, we prepared a series of novel triazole-conjugated dihydropyrimidinones using a synthetic approach that is well suited for obtaining compound libraries. Several of these dihydropyrimidinone derivatives modulate human P-glycoprotein (hPgp) activity with low micromolar EC₅₀ values. Molecular docking studies suggest that these compounds bind to the M-site of the transporter.



1. INTRODUCTION

Multidrug resistance (MDR) remains a deadly obstacle in anticancer treatments despite advances in understanding the molecular basis of this phenomenon. A key contributor to MDR is P-glycoprotein (Pgp), also known as multidrug resistance 1 protein (MDR1 gene), which is a membrane protein that couples ATP hydrolysis to the expulsion of small molecules, such as anticancer drugs, from the cell.¹ The resulting decrease in intracellular drug concentration leads to reduced chemosensitivity and, ultimately, drug resistance. The ability of human P-glycoprotein (hPgp) to adopt multiple conformations and its substrate promiscuity, however, complicate efforts to design potent inhibitors using rational, structure-based strategies. This problem is reinforced by the fact that several binding sites are located within the TM helices, which are believed to form a pathway by which small molecules cross the membrane. To the best of our knowledge, no hPgp inhibitors have been approved for clinical use in the last four decades, including third generation candidates such as zosuquidar, elacridar, and tariquidar.² New synthetic strategies are therefore needed to explore chemical space so as to obtain small molecules that can inhibit or at least modulate hPgp activity to overcome MDR.

In previous work in our laboratory, we found that functionalized 1,4-dihydropyridines had activity as hPgp inhibitors,³ which led to the discovery of compounds that combined anticancer activity with the ability to inhibit hPgp.⁴ Encouraged by this success, we are exploring whether alternate, synthetically available, and heterocyclic scaffolds represent novel leads for accessing hPgp inhibitors with improved

potency. We now report that the dihydropyrimidinone (DHPM) scaffold can also be functionalized to give hPgp inhibitors by means of chemical transformations that can be easily adapted to prepare diverse DHPM libraries.

Our work on the DHPM scaffold is motivated by literature showing that DHPM derivatives exhibit activity against a variety of anticancer targets. For example, DHPM derivative **I** (Figure 1) inhibits the sodium iodide symporter, which is a transmembrane glycoprotein associated with many types of cancer.⁵ Oxo-monastrol analogue **II** and its derivatives are cytotoxic,⁶ and *N*-phenyl DHPM derivatives of **III** inhibit Hsp90 at nanomolar concentrations.⁷ Lipophilic DHPM variants, such as **IV**, exhibit antiproliferative properties against two glioma cell lines,⁸ and derivatives of DHPM **V** are active against lung cancer cell lines at nanomolar concentrations.⁹ Finally, aryl- α -haloacrylamide-functionalized DHPMs, such as **VI**, show anticancer activity in the micromolar range by inhibiting tubulin polymerization.¹⁰

2. RESULTS AND DISCUSSION

Using a convergent synthetic sequence that combines the Biginelli reaction with CuAAC chemistry, we prepared a library

Received: October 18, 2021

Accepted: April 15, 2022

Published: May 2, 2022







Figure 1. Structures of known DHPMs [I–VI] with anticancer activity (see text for details).

Scheme 1. Synthetic Route for Preparing the Library of Novel DPHM Derivatives^a



^a(a) Propargyl bromide and DMF; (b) acetylacetone, urea, and PEG-400; (c) HCl, NaNO₂, and NaN₃; (d) 5a'–5h', sodium ascorbate, CuSO₄·5H₂O, and (2:1:2) *t*-butanol:DMF:H₂O.




Figure 2. Structures of selected TRZ-DHPMs for which IC₅₀ < 1.5 μ M against the Caco-2 cell line. Structures and biological data for the complete set of TRZ-DHPMs are provided in the Supporting Information.

of novel triazole-conjugated DHPM derivatives (TRZ-DHPMs) (Scheme 1). 1,2,3-Triazoles are easily prepared by copper-catalyzed alkyne–azide cycloaddition (CuAAC), thereby allowing the rapid construction of compounds capable of exhibiting a range of biological activities.^{11,12} As well as being straightforward to prepare, triazole substituents are present in clinically approved drugs¹³ and fungicides¹⁴ as well as in ligands that bind to a variety of cancer targets.^{15,16} Substituted hydroxybenzaldehydes 1a–1d were propargylated in the presence of cesium carbonate to give benzaldehydes 2a–2d,¹⁷ which were then reacted with acetyl acetone and urea following the Biginelli protocol¹⁸ to yield DHPM derivatives 3a–3d. These alkynes were then connected to the substituted phenylazides 5a'–5h' (prepared from the corresponding anilines 4a'–4h'¹⁹) in the presence of CuSO₄ and sodium ascorbate to give the target 4-aryl-5-acetyl-6-methyl-3,4-

dihydropyrimidin-2(1H)-ones 6 as racemic mixtures (Figure 2 and Table S1, Supporting Information). This coupling reaction gave the best yields when a 2:1:2 *t*-butanol:DMF:water mixture was used as solvent (Table S2, Supporting Information).

With these compounds in hand, we characterized their cytotoxicity against a colorectal adenocarcinoma (Caco-2) cell line using an MTT-based assay. Half maximal inhibition concentration (IC₅₀) values in the range of 0.6–3.7 μ M were obtained for the library of functionalized TRZ-DHPMs (Table S3, Supporting Information), which compares favorably to those observed for known drugs such as carboplatin (7 μ M), gemcitabine (5 μ M) and daunorubicin (14 μ M) under the same assay conditions (Table 1). The relatively small range of IC₅₀ values observed for this series of functionalized TRZ-DHPMs complicates efforts to develop any SAR models but

Table 1. Activities of Selected TRZ-DPHMs and Known Drugs

	compound	cytotoxicity, IC ₅₀ (μM)	inhibition of calcein extrusion, EC ₅₀ (μM)
1	6aa'	1.1 ± 0.2	12.56 ± 0.08
2	6ab'	1.3 ± 0.8	15.42 ± 0.06
3	6ad'	0.57 ± 0.03	3.14 ± 0.03
5	6bd'	0.76 ± 0.06	4.8 ± 0.2
6	6be'	0.8 ± 0.1	9.25 ± 0.02
7	6bh'	0.6 ± 0.2	4.2 ± 0.2
8	6ca'	0.9 ± 0.1	4.0 ± 0.2
9	6cb'	1.22 ± 0.08	3.4 ± 0.3
10	6cc'	1.25 ± 0.08	8.9 ± 0.1
11	carboplatin	7 ± 2	N.A.
12	gemcitabine	5 ± 1	N.A.
13	daunorubicin	14 ± 2	N.A.
14	verapamil	N.A.	9.52 ± 0.01
15	cyclosporin A	N.A.	5.36 ± 0.02

the presence of a halogen in the *N*-phenyl substitute of the triazole ring appears to correlate with sub-micromolar activity (e.g., **6ad'**, **6bd'**, and **6be'**). An *ortho*- rather than a *para*-relationship between the triazole and dihydropyrimidinone rings also appears important for increased cytotoxicity (Table S3, Supporting Information). The molecular basis for the cytotoxic activity of these TRZ-DHPMs, however, remains to be elucidated.

Despite a lack of information on the molecular mechanism of action, these nine cytotoxic TRZ-DHPMs were also assayed for their ability to reverse the hPgp-mediated efflux of calcein-AM, a lipophilic, non-fluorescent dye and a known Pgp substrate, from a Caco-2-VB cell line that expresses hPgp in much higher amounts and is resistant to vinblastine (Figure 3). In this assay, hydrolysis of intracellular calcein-AM to calcein by endogenous cellular esterases causes the cell to become highly fluorescent (see Figure S1 in Supporting Information). As a result, compounds that block the function of the hPgp efflux pump, which otherwise actively exports the dye from the cell, cause Caco-2-VB cells to accumulate calcein-AM, thereby increasing their fluorescence. The nine TRZ-DHPMs exhibiting the highest cytotoxicity were assayed for their ability to block calcein-AM release from Caco-2-VB cells (Table 1). The results of these experiments show that the TRZ-DHPMs **6ad'**, **6bd'**, **6be'**, **6bh'**, **6ca'**, **6cb'**, and **6cc'** exhibit similar or better efficacy than known Pgp substrates, cyclosporin A and verapamil (Table 1 and Figure 3). The most potent TRZ-DHPM, **6ad'**, has a chlorophenyl substituent attached to the triazole although replacing chlorine by an electron-withdrawing nitro group gives a 5-fold decrease in potency (**6ab'**). A similar decrease in potency is also observed when chlorine is replaced by hydrogen, raising the possibility that the ligand forms a σ -hole interaction with its target site in the ATP-dependent efflux pump. Remarkably, the presence of bromine substitution in the phenyl substituent of the dihydropyrimidinone (**6cb'**) overcomes the effects of the nitro group and restores hPgp inhibition. Fluorescence microscopy measurements confirmed intracellular calcein retention when Caco-2-VB cells were treated with 1 μM calcein-AM in the presence of TRZ-DHPMs **6ad'**, **6ca'**, **6cb'**, cyclosporin A, and verapamil (Figure 3). Statistical analysis also showed that that **6ad'** ($p < 0.0001$) is a better modulator of hPgp function than either cyclosporin A or verapamil. Thus, these compounds have dual activity although




Figure 3. Top: Dose-dependent dye retention in Caco-2 VB cells treated with selected TRZ-DHPMs in the calcein-AM uptake assay. Bottom: (A) Fluorescence microscopy imaging of intracellular calcein in (a) untreated Caco-2 VB cells and Caco-2 VB cells 30 min after being treated with (b) TRZ-DHPM **6ad'**, (c) verapamil, (d) cyclosporin A, (e) TRZ-DHPM **6cb'**, and (f) TRZ-DHPM **6ca'**. TRZ-DHPM concentrations correspond to the relevant EC₅₀ value (Table 1). (B) Graphical representation of calcein retention after treatment with TRZ-DHPMs **6ad'**, **6cb'**, and **6ca'**. Data are represented as mean ± SEM with p value ($*p < 0.001$) as compared to verapamil and cyclosporin A. Calcein retention in Caco-2 cells was used as a negative control. Full details are provided in the Supporting Information.

their cytotoxicity is unlikely to be associated with their ability to modulate hPgp efflux activity.

As in a recent study of small-molecule hPgp inhibitors,²⁰ molecular modeling was used to obtain insights into how these DHPM derivatives might inhibit this transporter. Given the unavailability of high-resolution experimental coordinates for the “inward”-facing conformation of hPgp, we built a homology model of hPgp based on the experimental structure of *Mus musculus* Pgp, which has an 87% sequence match to hPgp,²¹ using well-precedented methods (see the Supporting Information).²² Energy minimization and equilibration using molecular dynamics (MD) simulations (100 ns) gave an inward-facing structure (Figure 4A) that is consistent with a low-resolution (3.6 Å) cryoEM structure of hPgp (occluded conformation).²³ Molecular docking was used to examine how TRZ-DHPM **6ad'** might bind to the M-, R-, H-, and ATP-binding sites²⁴ of the efflux pump. Thus, the (R) and (S) enantiomers of TRZ-DHPM **6ad'** were docked into the four potential binding sites of hPgp and evaluated using the scoring function implemented in GLIDE.²⁵ We observed that (S)-**6ad'** exhibited little energetic preference for any of the binding sites (Table S4, Supporting Information), suggesting that this enantiomer might easily be transported out of the cell by hPgp. In contrast, the (R)-**6ad'** was predicted to bind more tightly to the M-site (−8.8 kcal mol^{−1}) than to the H- and R-sites (−3.7 and −6.5 mol^{−1}). As neither enantiomer could be docked into the ATP-binding site, our docking calculations lead to the hypothesis that (R)-**6ad'** blocks hPgp activity, a

°C for 3–5 h. After cooling to RT, the reaction mixture was poured into water, and the solid product was removed by filtration before being recrystallized from EtOH. White solid; 5.4 g, 59%; ¹H NMR (DMSO-*d*₆): δ 9.19 (s, 1H, NH), 8.96 (s, 1H, NH), 7.52 (m, 2H, ArH), 7.20 (m, 2H, ArH) 5.24 (s, 3H, 1 × CH₂ and 1 × CH), 2.29 (s, 3H, COCH₃), 2.09 (s, 3H, CH₃). ¹³C NMR (DMSO-*d*₆): δ 192.3, 155.2, 151.0, 147.3, 128.8, 127.3, 126.9, 125.6, 114.6, 108.5, 78.8, 75.8, 53.1, 51.3, 30.2, 18.8.

The following compounds were prepared using the same synthetic procedure as described for 3a.

4.3.6. 5-Acetyl-6-methyl-4-(4-(prop-2-yn-1-yloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one (3b). Compound 3b was prepared from aldehyde 2b (5.0 g, 32.0 mmol), urea (1.92 g, 32 mmol), acetyl acetone (3.2 mL, 32 mmol), and PEG (4.0 g). White solid; 4.5 g, 49.5%; ¹H NMR (DMSO-*d*₆): δ 9.19 (s, 1H, NH), 8.96 (s, 1H, NH), 7.52 (d, *J* = 7.8 Hz, 2H, ArH), 7.20 (d, *J* = 7.8 Hz, 2H, ArH) 5.24 (s, 3H, 1 × CH₂ and 1 × CH), 2.29 (s, 3H, COCH₃), 2.09 (s, 3H, CH₃). ¹³C NMR (DMSO-*d*₆): δ 192.3, 155.2, 151.0, 147.1, 136.8, 126.9, 114.6, 108.5, 78.8, 75.8, 53.1, 51.3, 30.2, 18.8.

4.3.7. 5-Acetyl-4-(3,5-dibromo-2-(prop-2-yn-1-yloxy)phenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (3c). Compound 3c was prepared from 2c (6.5 g, 23.2 mmol), urea (1.39 g, 23.2 mmol), acetyl acetone (2.3 mL, 23.2 mmol), and PEG (4.0 g). Cream solid; 4.5 g, 44%; ¹H NMR (DMSO-*d*₆): δ 9.35 (s, 1H, NH), 9.05 (s, 1H, NH), 7.28 (s, 1H, ArH), 7.21 (s, 1H, ArH), 5.64 (s, 1H, CH), 5.44–5.31 (m, 1 × CH₂ and 1 × CH), 2.37 (s, 3H, COCH₃), 2.13 (s, 3H, CH₃). ¹³C NMR (DMSO-*d*₆): δ 193.1, 152.5, 150.4, 146.7, 131.6, 128.7, 125.5, 117.1, 115.5, 108.8, 77.8, 76.5, 55.3, 49.3, 27.6, 18.1.

4.3.8. 5-Acetyl-4-(2-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (3d). Compound 3d was prepared from 2d (4.0 g, 26.3 mmol), urea (1.58 g, 26.3 mmol), acetyl acetone (2.6 mL, 26.3 mmol), and PEG (4.0 g). Cream solid; 3.9 g, 47%; ¹H NMR (DMSO-*d*₆): δ 9.17 (s, 1H, NH), 8.92 (s, 1H, NH), 7.91 (d, *J* = 7.7 Hz, 2H, ArH), 7.79 (s, 1H, ArH), 5.22 (s, 1H, 1 × CH), 5.18 (s, 3H, 1 × CH₂ and 1 × CH), 3.67 (s, 3H, OCH₃), 2.20 (s, 3H, COCH₃), 2.09 (s, 3H, CH₃). ¹³C NMR (DMSO-*d*₆): δ 194.4, 152.1, 148.0, 146.6, 143.8, 136.5, 128.7, 122.9, 120.1, 117.9, 110.9, 109.1, 61.6, 55.3, 53.4, 30.1, 18.8.

4.4. General Procedure for the Preparation of Phenylazides. A solution of aq. NaNO₂ (5 mmol) was added dropwise to a solution of the aniline (5 mmol) dissolved in 6 N HCl (20 mL) so as to maintain the temperature within a range of 0–5 °C. After stirring at 0–5 °C for 1 h, a solution of aq. NaN₃ (6 mmol, 1.2 equiv) was added dropwise to the reaction mixture. The reaction was then allowed to warm and stirred at RT for 6–8 h with progress being monitored by TLC. On completion, the reaction mixture was poured into cold water. The aqueous solution was extracted with EtOAc and the combined extracts were then washed with brine and aq. NaHCO₃ before being dried over Na₂SO₄. Concentration of the solution under vacuum gave the desired phenylazide.

4.5. General Procedure for Synthesis of 5-Acetyl-6-methyl-Substituted 1,2,3-Triazol-4-yl)methoxyphenyl)-3,4-dihydropyrimidin-2(1H)-one (6aa'–6dc'). A mixture of substituted 5-acetyl-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-one 3 (1 equiv) and phenylazide 5 (1.2 equiv) was charged into a sealed tube containing a solution of *tert*-butanol, DMF, and water (2:1:2, v/v, 5 mL). To this charged assembly, copper(II) sulfate (5 mol %) and sodium ascorbate

(1 equiv) were added. The reaction was continued under stirring for 20–24 h at rt. After completion of the reaction (confirmed by TLC), the reaction mixture was filtered under vacuum and washed with water.

Using the above general synthetic procedure, compounds 6aa'–6dc' were synthesized.

4.5.1. 5-Acetyl-6-methyl-4-(2-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one (6aa'). Compound 6aa' was prepared from 3a (300 mg, 1.0 mmol) and azidobenzene (143 mg, 1.2 mmol). Pale yellow solid; 320 mg, 75%, Melting point: 145–147 °C. ¹H NMR (DMSO-*d*₆): δ 9.18 (s, 1H, NH), 8.96 (s, 1H, NH), 7.92 (d, *J* = 7.8 Hz, 2H, ArH), 7.64–7.60 (m, 2H, ArH), 7.51 (d, *J* = 7.3 Hz, 1H, ArH), 7.35 (s, 1H, ArH), 7.30–7.27 (m, 2H, ArH), 7.08 (d, *J* = 7.3 Hz, 1H, ArH), 6.95–6.92 (m, 1H, ArH), 5.66 (s, 1H, CH), 5.38 (s, 2H, CH₂), 2.29 (s, 3H, COCH₃), 2.00 (s, 3H, CH₃). ¹³C NMR (DMSO-*d*₆): δ 194.5, 154.8, 152.1, 148.3, 144.2, 136.5, 131.5, 129.9, 128.9, 128.7, 127.0, 122.5, 121.1, 120.1, 112.8, 107.7, 61.6, 48.6, 29.7, 18.6. MS (EI) *m/z* M⁺ 403.

4.5.2. 5-Acetyl-6-methyl-4-(2-((2-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one (6ab'). Compound 6ab' was prepared from 3a (300 mg, 1.0 mmol) and 5b' (197 mg, 1.2 mmol). Orange solid; 275 mg, 58%, Melting point: 133–135 °C. ¹H NMR (DMSO-*d*₆): δ 9.17 (s, 1H, NH), 8.89 (s, 1H, NH), 8.24 (d, *J* = 7.8 Hz, 1H, ArH), 8.00–7.96 (m, 1H, ArH), 7.93–7.91 (m, 1H, ArH) 7.86 (d, *J* = 7.4 Hz, 1H, ArH), 7.34 (s, 1H, ArH), 7.31–7.28 (m, 2H, ArH), 7.10 (d, *J* = 7.3 Hz, 1H, ArH), 6.97–6.94 (m, 1H, ArH), 5.66 (s, 1H, CH), 5.38 (s, 2H, CH₂), 2.29 (s, 3H, COCH₃), 2.00 (s, 3H, CH₃). ¹³C NMR (DMSO-*d*₆): δ 194.5, 154.8, 152.1, 148.2, 144.1144.0, 134.3, 131.6, 131.2, 129.0, 128.9, 127.5, 127.1, 125.6, 125.5, 121.2, 112.9, 107.7, 61.6, 48.5, 29.7, 18.6. MS: *m/z* [M - C₉H₇N₄O₂]⁺ 245; Anal. calcd. for C₂₂H₂₀N₆O₅: C, 58.92; H, 4.50; N, 18.74. Found: C, 58.79; H, 4.61; N, 17.85 (%).

4.5.3. 5-Acetyl-6-methyl-4-(2-((4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one (6ac'). Compound 6ac' was prepared from 3a (300 mg, 1.0 mmol) and 5c' (197 mg, 1.2 mmol). Pale yellow solid; 332 mg, 70%, Melting point: 148–150 °C. ¹H NMR (DMSO-*d*₆): δ 9.17 (s, 2H, 2 × NH), 8.48 (d, *J* = 8.4 Hz, 2H, ArH), 8.25 (d, *J* = 8.4 Hz, 2H, ArH), 7.36–7.28 (m, 3H, ArH), 7.09 (d, *J* = 7.1 Hz, 2H, ArH), 5.66 (s, 1H, CH), 5.39 (s, 2H, CH₂), 2.29 (s, 3H, COCH₃), 2.01 (s, 3H, CH₃). ¹³C NMR (DMSO-*d*₆): δ 194.4, 154.8, 152.1, 148.3, 146.7, 144.9, 140.7, 131.5, 128.9, 127.1, 125.5, 121.1, 120.6, 120.0, 112.8, 107.7, 61.5, 48.7, 29.7, 18.6. MS: *m/z* M⁺ 448; Anal. calcd. for C₂₂H₂₀N₆O₅: C, 58.92; H, 4.50; N, 18.74. Found: C, 58.73; H, 4.53; N, 17.67 (%).

4.5.4. 5-Acetyl-4-(2-((3-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (6ad'). Compound 6ad' was prepared from 3a (300 mg, 1.0 mmol) and 5d' (193 mg, 1.2 mmol). Pale cream solid; 340 mg, 73%, Melting point: 130–132 °C. ¹H NMR (DMSO-*d*₆): δ 9.20 (s, 1H, NH), 9.05 (s, 1H, NH), 8.06 (s, 1H, ArH), 7.96–7.94 (m, 1H, ArH) 7.64 (t, *J* = 8.0 Hz, 1H, ArH), 7.57 (d, *J* = 8.0 Hz, 1H, ArH), 7.75–7.26 (m, 3H, ArH) 7.12–7.10 (m, 1H, ArH) 7.11 (d, *J* = 7.4 Hz, 1H, ArH), 6.97–6.93 (m, 1H, ArH), 5.68 (s, 1H, CH), 5.38 (s, 2H, CH₂), 2.31 (s, 3H, COCH₃), 2.03 (s, 3H, CH₃). ¹³C NMR (DMSO-*d*₆): δ 194.4, 154.8, 152.1, 148.3, 144.4, 137.5, 134.1, 131.6, 131.5, 128.9, 129.5, 127.1, 122.7, 121.1, 119.8, 118.6, 112.8, 107.7,

61.6, 48.7, 29.7, 18.6. MS (EI) m/z $[M - C_2H_3O]^+$ 394; Anal. calcd. for $C_{22}H_{20}ClN_5O_3$: C, 60.35; H, 4.60; N, 15.99. Found: C, 60.37; H, 4.56; N, 15.94 (%).

4.5.5. 5-Acetyl-6-methyl-4-((1-(2,4,6-trichlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-3,4-dihydro-pyrimidin-2(1H)-one (6af'). Compound **6af'** was prepared from **3a** (300 mg, 1.0 mmol) and **5f'** (267 mg, 1.2 mmol). Light yellow solid; 405 mg, 76%, Melting point: 139–141 °C. 1H NMR (DMSO- d_6): δ 9.15 (s, 1H, NH), 8.78 (s, 1H, NH), 8.26–8.22 (m, 2H, ArH), 7.30–7.24 (m, 3H, ArH), 7.09–7.08 (m, 1H, ArH), 6.95 (s, 1H, ArH), 5.63 (s, 1H, CH), 5.38 (s, 2H, CH₂), 2.28 (s, 3H, COCH₃), 2.00 (s, 3H, CH₃). ^{13}C NMR (DMSO- d_6): δ 194.4, 154.8, 152.0, 148.2, 143.4, 137.2, 134.0, 133.7, 131.7, 129.5, 128.9, 127.3, 126.6, 122.8, 121.1, 112.9, 107.7, 61.5, 48.6, 29.7, 18.6. MS: m/z M^+ 505; Anal. calcd. for $C_{22}H_{18}Cl_3N_5O_3$: C, 52.14; H, 3.58; N, 13.82. Found: C, 52.19; H, 3.56; N, 13.81 (%).

4.5.6. 5-Acetyl-6-methyl-4-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one (6ba'). Compound **6ba'** was prepared from **3b** (300 mg, 1.0 mmol) and **5a'** (143 mg, 1.2 mmol). Cream solid; 365 mg, 85%, Melting point: 133–135 °C. 1H NMR (DMSO- d_6): δ 9.19 (s, 1H, NH), 8.96 (s, 1H, NH), 7.92 (d, J = 7.8 Hz, 2H, ArH), 7.80 (s, 1H, ArH), 7.62–7.58 (m, 2H, ArH), 7.52–7.48 (m, 1H, ArH), 7.20 (d, J = 8.5 Hz, 2H, ArH), 7.04 (d, J = 8.5 Hz, 2H, ArH), 5.22 (s, 3H, 1 \times CH₂ and 1 \times CH), 2.29 (s, 3H, COCH₃), 2.09 (s, 3H, CH₃). ^{13}C NMR (DMSO- d_6): δ 194.3, 157.2, 152.1, 147.8, 143.8, 136.8, 136.5, 129.8, 128.7, 127.6, 122.8, 120.1, 114.6, 109.5, 60.98, 53.2, 30.2, 18.8. MS: m/z M^+ 403; Anal. calcd. for $C_{22}H_{21}N_5O_3$: C, 65.50; H, 5.25; N, 17.36. Found: C, 65.54; H, 5.27; N, 17.31 (%).

4.5.7. 5-Acetyl-6-methyl-4-((1-(2-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one (6bb'). Compound **6bb'** was prepared from **3b** (300 mg, 1.0 mmol) and **5b'** (197 mg, 1.2 mmol). Orange solid; 345 mg, 73%, Melting point: 157–159 °C. 1H NMR (DMSO- d_6): δ 9.20 (s, 1H, NH), 9.18 (s, 1H, NH), 8.75 (s, 1H, ArH), 8.43–8.33 (m, 2H, ArH), 7.92–7.88 (m, 1H, ArH), 7.80–7.78 (m, 1H, ArH), 7.19 (d, J = 7.9 Hz, 2H, ArH), 7.04 (d, J = 7.9 Hz, 2H, ArH), 5.24 (s, 2H, CH₂), 5.22 (s, 1H, CH), 2.28 (s, 3H, COCH₃), 2.09 (s, 3H, CH₃). ^{13}C NMR (DMSO- d_6): δ 194.3, 157.1, 152.0, 148.4, 147.9, 144.3, 137.0, 136.8, 131.5, 127.6, 126.1, 123.2, 123.1, 120.3, 114.6, 109.5, 60.8, 53.1, 30.2, 18.8. MS: m/z M^+ 448; Anal. calcd. for $C_{22}H_{20}N_6O_5$: C, 58.92; H, 4.50; N, 18.74. Found: C, 58.89; H, 4.53; N, 18.70 (%).

4.5.8. 5-Acetyl-6-methyl-4-((1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one (6bc'). Compound **6bc'** was prepared from **3b** (300 mg, 1.0 mmol) and **5c'** (197 mg, 1.2 mmol). Orange solid; 351 mg, 74%, Melting point: 134–136 °C. 1H NMR (DMSO- d_6): δ 9.18 (s, 2H, 2 \times NH), 8.46 (d, J = 9.2 Hz, 2H, ArH), 8.25 (d, J = 9.2 Hz, 2H, ArH), 7.80 (s, 1H, ArH), 7.19 (d, J = 8.8 Hz, 2H, ArH), 7.04 (d, J = 8.8 Hz, 2H, ArH), 5.24 (s, 2H, CH₂), 5.21 (s, 1H, CH), 2.28 (s, 3H, COCH₃), 2.09 (s, 3H, CH₃). ^{13}C NMR (DMSO- d_6): δ 194.3, 157.1, 152.0, 147.9, 146.7, 144.5, 140.7, 136.9, 127.6, 125.5, 123.2, 120.6, 114.6, 109.5, 60.8, 53.1, 30.2, 18.8. MS: m/z M^+ 448; Anal. Calcd. for $C_{22}H_{20}N_6O_5$: C, 58.92; H, 4.50; N, 18.74. Found: C, 58.90; H, 4.51; N, 18.76 (%).

4.5.9. 5-Acetyl-4-((1-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (6bd'). Compound **6bd'** was prepared from **3b** (300 mg, 1.0 mmol) and **5d'** (193 mg, 1.2 mmol). White solid; 380 mg,

82%, Melting point: 142–144 °C. 1H NMR (DMSO- d_6): δ 9.22 (s, 1H, NH), 9.04 (s, 1H, NH), 8.07 (s, 1H, ArH), 7.93–7.95 (m, 1H, ArH), 7.84 (s, 1H, ArH), 7.62–7.57 (m, 2H, ArH), 7.23 (d, J = 7.3 Hz, 2H, ArH), 7.06 (d, J = 7.3 Hz, 2H, ArH), 5.24 (s, 3H, 1 \times CH₂ and 1 \times CH), 2.31 (s, 3H, COCH₃), 2.11 (s, 3H, CH₃). ^{13}C NMR (DMSO- d_6): δ 194.3, 157.2, 152.1, 147.9, 144.0, 137.5, 136.8, 134.1, 131.5, 128.4, 127.7, 122.9, 119.8, 118.6, 114.6, 109.5, 60.8, 53.2, 30.1, 18.8. MS: m/z M^+ 437; Anal. calcd. for $C_{22}H_{20}ClN_5O_3$: C, 60.35; H, 4.60; N, 15.99. Found: C, 60.32; H, 4.58; N, 16.01 (%).

4.5.10. 5-Acetyl-4-((1-(3-bromophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (6be'). Compound **6be'** was prepared from **3b** (300 mg, 1.0 mmol) and **5e'** (251 mg, 1.2 mmol). Cream solid; 384 mg, 70%, Melting point: 138–140 °C. 1H NMR (DMSO- d_6): δ 9.21 (s, 1H, NH), 9.04 (s, 1H, NH), 8.19 (s, 1H, ArH), 7.99–7.97 (m, 1H, ArH), 7.82 (s, 1H, ArH), 7.70 (d, J = 8.0 Hz, 1H, ArH), 7.56 (t, J = 8.0 Hz, 1H, ArH), 7.22 (d, J = 8.2 Hz, 2H, ArH), 7.05 (d, J = 8.2 Hz, 2H, ArH), 5.23 (s, 3H, 1 \times CH₂ and 1 \times CH), 2.30 (s, 3H, COCH₃), 2.10 (s, 3H, CH₃). ^{13}C NMR (DMSO- d_6): δ 194.3, 157.1, 152.1, 147.9, 144.0, 137.6, 136.8, 131.7, 131.4, 127.7, 122.6, 119.0, 114.6, 109.5, 60.9, 53.2, 30.2, 18.8. MS: m/z $[M - C_2H_3O]^+$ 438.

4.5.11. 5-Acetyl-6-methyl-4-((1-(2,4,6-trichlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-3,4-dihydro-pyrimidin-2(1H)-one (6bf'). Compound **6bf'** was prepared from **3b** (300 mg, 1.0 mmol) and **5f'** (267 mg, 1.2 mmol). Light yellow solid; 420 mg, 78%, Melting point: 135–137 °C. 1H NMR (DMSO- d_6): δ 9.18 (s, 1H, NH), 8.73 (s, 1H, NH), 8.26 (s, 1H, ArH), 8.22 (s, 1H, ArH), 7.80 (s, 1H, ArH), 7.18 (d, J = 8.6 Hz, 2H, ArH), 7.03 (d, J = 8.6 Hz, 2H, ArH), 5.22 (s, 2H, CH₂), 5.21 (s, 1H, CH), 2.28 (s, 3H, COCH₃), 2.09 (s, 3H, CH₃). ^{13}C NMR (DMSO- d_6): δ 194.3, 157.2, 152.0, 147.9, 142.9, 136.8, 134.0, 133.8, 131.6, 130.9, 129.7, 128.4, 127.6, 126.9, 114.6, 109.5, 60.8, 53.1, 30.2, 18.8. MS: m/z M^+ 505; Anal. calcd. for $C_{22}H_{18}Cl_3N_5O_3$: C, 52.14; H, 3.58; N, 13.82. Found: C, 52.11; H, 3.61; N, 13.80 (%).

4.5.12. 5-Acetyl-4-((1-(2,4-dimethoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-6-methyl-3,4-dihydro-pyrimidin-2(1H)-one (6bh'). Compound **6bh'** was prepared from **3b** (300 mg, 1.0 mmol) and **5h'** (227 mg, 1.2 mmol). White solid; 400 mg, 82%, Melting point: 140–142 °C. 1H NMR (DMSO- d_6): δ 9.18 (s, 1H, NH), 8.89 (s, 1H, NH), 7.80 (s, 1H, ArH), 7.48 (s, 1H, ArH), 7.43–7.41 (m, 1H, ArH), 7.19 (d, J = 8.0 Hz, 2H, ArH), 7.14–7.12 (m, 1H, ArH), 7.04 (d, J = 8.0 Hz, 2H, ArH), 5.20 (s, 3H, 1 \times CH₂ and 1 \times CH), 3.86 (s, 3H, OCH₃), 3.82 (s, 3H, OCH₃), 2.29 (s, 3H, COCH₃), 2.09 (s, 3H, CH₃). ^{13}C NMR (DMSO- d_6): δ 194.2, 157.2, 152.1, 149.2, 148.8, 147.8, 143.5, 136.8, 129.9, 127.6, 122.8, 114.7, 114.6, 112.1, 109.5, 104.6, 61.0, 55.8, 55.7, 53.2, 30.2, 18.8. MS: m/z M^+ 463.

4.5.13. 5-Acetyl-4-(3,5-dibromo-2-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (6ca'). Compound **6ca'** was prepared from **3c** (442 mg, 1.0 mmol) and **5a'** (143 mg, 1.2 mmol). Yellow solid; 263 mg, 47%, Melting point: 157–159 °C. 1H NMR (DMSO- d_6): δ 9.35 (s, 1H, NH), 9.05 (s, 1H, NH), 7.97–7.95 (m, 2H, ArH), 7.86–7.85 (m, 1H, ArH), 7.74 (s, 1H, ArH), 7.65–7.61 (m, 2H, ArH), 7.54–7.52 (m, 1H, ArH), 7.28 (s, 1H, ArH), 5.74 (s, 1H, CH), 5.44–5.31 (m, 2H, CH₂), 2.37 (s, 3H, COCH₃), 2.18 (s, 3H, CH₃). ^{13}C NMR (DMSO- d_6): δ 194.1, 151.7, 151.4, 149.0, 143.7, 141.8, 136.5, 134.6, 129.8, 129.7,

128.7, 123.0, 120.2, 118.5, 117.7, 108.8, 66.4, 49.3, 30.6, 19.1. MS: m/z $[M - C_9H_8N_3]^+$ 403.

4.5.14. 5-Acetyl-4-(3,5-dibromo-2-((1-(2-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (6cb'). Compound **6cb'** was prepared from **3c** (442 mg, 1.0 mmol) and **5b'** (197 mg, 1.2 mmol). Yellow solid; 273 mg, 45%, Melting point: 167–169 °C. 1H NMR (DMSO- d_6): δ 9.34 (s, 1H, NH), 8.97 (s, 1H, NH), 8.26–8.24 (m, 1H, ArH), 8.01–7.81 (m, 4H, ArH), 7.75 (s, 1H, ArH), 7.28 (s, 1H, ArH), 5.74 (s, 1H, CH), 5.46–5.18 (m, 2H, CH₂), 2.28 (s, 3H, COCH₃), 2.18 (s, 3H, CH₃). ^{13}C NMR (DMSO- d_6): δ 194.2, 151.5, 151.3, 149.0, 144.0, 143.3, 142.0, 134.5, 134.4, 131.2, 129.7, 129.0, 127.6, 126.2, 125.5, 118.5, 117.6, 108.9, 66.2, 49.3, 30.6, 19.1. MS: m/z $[M - C_9H_7N_4O_2]^+$ 403.

4.5.15. 5-Acetyl-4-(3,5-dibromo-2-((1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (6cc'). Compound **6cc'** was prepared from **3c** (442 mg, 1.0 mmol) and **5c'** (197 mg, 1.2 mmol). Brown solid; 273 mg, 45%, Melting point: 165–167 °C. 1H NMR (DMSO- d_6): δ 9.36 (s, 1H, NH), 9.27 (s, 1H, NH), 8.48 (d, 2H, J = 8.2 Hz, ArH), 8.37 (d, 2H, J = 8.2 Hz, ArH), 7.85 (s, 1H, ArH), 7.74 (s, 1H, ArH), 7.28 (s, 1H, ArH), 5.73 (s, 1H, CH), 5.39 (dd, J = 12.0 Hz and 8.0 Hz, 2H, CH₂), 2.38 (s, 3H, COCH₃), 2.19 (s, 3H, CH₃). ^{13}C NMR (DMSO- d_6): δ 194.1, 151.5, 149.1, 146.7, 144.3, 143.6, 141.8, 140.7, 134.6, 129.7, 125.3, 123.5, 120.5, 118.5, 117.6, 108.8, 66.2, 49.3, 30.6, 19.1.

4.5.16. 5-Acetyl-4-(3-methoxy-4-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (6da'). Compound **6da'** was prepared from **3d** (314 mg, 1.0 mmol) and **5a'** (143 mg, 1.2 mmol). White solid; 200 mg, 46%, Melting point: 151–153 °C. 1H NMR (DMSO- d_6): δ 9.17 (s, 1H, NH), 8.92 (s, 1H, NH), 7.92–7.90 (m, 2H, ArH), 7.79 (s, 1H, ArH), 7.62–7.59 (m, 2H, ArH), 7.52–7.48 (m, 1H, ArH), 7.13–7.11 (m, 1H, ArH), 6.94 (s, 1H, ArH), 6.74–6.72 (m, 1H, ArH), 5.22 (s, 1H, CH), 5.18 (s, 2H, CH₂), 3.67 (s, 3H, OCH₃), 2.20 (s, 3H, COCH₃), 2.09 (s, 3H, CH₃). ^{13}C NMR (DMSO- d_6): δ 194.4, 152.1, 148.9, 148.0, 146.6, 143.8, 137.3, 136.5, 129.8, 128.7, 122.9, 120.1, 117.9, 113.7, 110.9, 109.1, 61.6, 55.3, 53.4, 30.1, 18.8. MS: m/z M^+ 433; Anal. calcd. for $C_{23}H_{23}N_5O_4$: C, 63.73; H, 5.35; N, 16.16. Found: C, 63.71; H, 5.39; N, 16.14 (%).

4.5.17. 5-Acetyl-4-(3-methoxy-4-((1-(2-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (6db'). Compound **6db'** was prepared from **3d** (314 mg, 1.0 mmol) and **5b'** (197 mg, 1.2 mmol). Yellow solid; 196 mg, 41%, Melting point: 153–155 °C. 1H NMR (DMSO- d_6): δ 9.18 (s, 1H, NH), 8.83 (s, 1H, NH), 8.24–8.22 (m, 1H, ArH), 7.98–7.94 (m, 1H, ArH), 7.90–7.85 (m, 2H, ArH), 7.83–7.80 (m, 1H, ArH), 7.14–7.11 (m, 1H, ArH), 6.95 (s, 1H, ArH), 6.75–6.73 (m, 1H, ArH), 5.24 (s, 1H, CH), 5.20 (s, 2H, CH₂), 3.73 (s, 3H, OCH₃), 2.30 (s, 3H, COCH₃), 2.10 (s, 3H, CH₃). ^{13}C NMR (DMSO- d_6): δ 194.4, 152.1, 148.9, 148.0, 146.7, 144.0, 143.5, 137.4, 134.3, 131.1, 129.0, 127.6, 126.0, 125.5, 117.9, 113.7, 110.9, 109.1, 61.5, 55.3, 53.4, 30.1, 18.8. MS: m/z $[M - C_2H_3O]^+$ 435; Anal. calcd. for $C_{23}H_{22}N_6O_6$: C, 57.74; H, 4.63; N, 17.56. Found: C, 57.78; H, 4.66; N, 17.51 (%).

4.5.18. 5-Acetyl-4-(3-methoxy-4-((1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (6dc'). Compound **6dc'** was prepared from **3b** (314 mg, 1.0 mmol) and **5c'** (197 mg, 1.2 mmol).

Brown solid; 210 mg, 44%, Melting point: 159–161 °C. 1H NMR (DMSO- d_6): δ 9.18 (s, 1H, NH), 9.15 (s, 1H, NH), 8.46–8.44 (m, 2H, ArH), 8.25–8.24 (m, 2H, ArH), 7.79 (s, 1H, ArH), 7.13–7.11 (m, 1H, ArH), 6.95 (s, 1H, ArH), 6.74–6.72 (m, 1H, ArH), 5.22 (s, 3H, 1 \times CH and 1 \times CH₂), 3.74 (s, 3H, OCH₃), 2.30 (s, 3H, COCH₃), 2.10 (s, 3H, CH₃). ^{13}C NMR (DMSO- d_6): δ 194.4, 152.1, 148.9, 148.0, 146.7, 144.5, 140.7, 137.5, 125.5, 123.3, 120.6, 117.9, 113.7, 110.9, 109.1, 61.5, 55.3, 53.4, 31.2, 30.1, 18.8. MS: m/z M^+ 478.

4.6. Biology. **4.6.1. Cell Culture.** The colorectal adenocarcinoma Caco-2 cell line was generously provided by the Zydus Research Centre, Ahmedabad, Gujarat, India. These cells were maintained in DMEM (Hi-Media) containing 25 mM HEPES buffer, 1000 mg/L glucose, L-glutamine, sodium bicarbonate, and sodium pyruvate and supplemented with 20% heat-inactivated FBS (cell clone), 1% (v/v) minimal essential medium nonessential amino acids (Hi-Media), antibiotic, and antimycotic (penicillin, streptomycin, and amphotericin B; Hi-Media) in a humidified atmosphere of 5% CO₂ at 37 °C. Cells were rinsed and split with trypsin–EDTA at 70–80% confluency, and only those cells exhibiting more than 90% viability were used in the biological assays. Caco-2 VB cells, which overexpress hPgp, were generated by growing Caco-2 cells in the presence of 1 μ g/mL vinblastine. The drug was removed from the culture medium 2–3 days prior to using the Caco-2 VB cells in the biological assays.

4.6.2. MTT Assay. Caco-2 cells were cultured in 96-well plates until they reached 70–80% confluency and then treated with the TRZ-DHPM derivatives (0.1–100 μ M). Cytotoxicity was determined using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay as described previously.³¹ Stock solutions of the TRZ-DHPM derivatives contained DMSO, but the final DMSO concentration in each assay did not exceed 0.1%.

4.6.3. hPgp-Mediated Efflux Assay. hPgp-mediated efflux in Caco-2 VB cells was measured using the Vybrant Multidrug Resistance Assay Kit (V-13180, Thermo Fisher Scientific). Each well contained 100 μ L of cells in culture medium, 50 μ L of a solution containing the TRZ-DHPM derivative, and 50 μ L of calcein-AM (total volume, 200 μ L). The final concentration of putative hPgp inhibitor in each assay ranged from 0.01 to 30 μ g/mL. Verapamil and cyclosporin A, both hPgp inhibitors, were used over the same concentration range as that used for the TRZ-DHPM derivatives. Caco-2 cells were used as a negative control (Figure S1). Cells were incubated at 37 °C for 15 min after the addition of TRZ-DHPM derivatives before 1 μ M calcein-AM was added to each well (0.25 μ M final concentration). After an additional 15 min at 37 °C, cells were washed with cold tissue culture medium (200 μ L), and calcein retention was measured by the increase in intracellular fluorescence. PBS was used for all dilutions. All experiments were performed in triplicate.

4.6.4. Cell Viability Assay. Cell viability was checked using a Trypan blue dye exclusion assay as described previously.³¹ In this assay, the % of viable cells was determined by Automated Cell Counter TC10 (BioRad) based on their capacity to uptake dye that differentiates live and dead cells. Live cells exclude dye due to their intact membrane, and dye penetrates the cell membrane of dead cells.

4.6.5. Data Analysis. The effectiveness of inhibitors on Pgp efflux activity, i.e., calcein retention was calculated by the following equation

$$\text{calcein retention} = \frac{\text{FT}}{\text{FU}} \times 100$$

where FT is the fluorescence of treated cells and FU is the fluorescence of untreated cells.

4.7. Computational Methods. **4.7.1. Homology Modeling.** A hPgp model was built using the multiple-template approach implemented in Modeller 9v14.³² Experimental coordinates 3G60 and 3G5U from *M. musculus* and 4F4C from *C. elegans* having high sequence similarity with human Pgp were used as templates for homology modeling.³³ The preparation of the hPgp model involved hydrogen addition and the removal of water molecules, followed by minimization using the Impact module of Schrödinger. The quality of the hPgp model was assessed using the pdbsum server.³⁴ A total of 96.4% residues were found to be in the allowed region with 86.7% in the most favored region.

4.7.2. Molecular Dynamics Simulation. Molecular dynamics (MD) simulations were performed on the final hPgp model using the Desmond software package. Lipid bilayer position coordinates were obtained from the Orientations of Proteins in Membranes (OPM) database.³⁵ The Desmond membrane insertion tab was then used to place the transmembrane (TM) coordinates. Further solvation of the model was done with TIP4P model in the cubic periodic boundary box. The resulting system of 76,326 atoms was minimized and pre-equilibrated by standard procedures implemented in Desmond. The distance between the box wall and hPgp model was set to be greater than 10 Å, thereby avoiding direct interactions with the periodic images. Steepest descent energy minimization was carried out until the gradient threshold (25 kcal/mol/Å), followed by L-BFGS (low-memory Broyden–Fletcher–Goldfarb–Shanno quasi-Newtonian minimizer) until a convergence threshold of 1 kcal/mol/Å was met. Further MD simulations were carried on the equilibrated systems for a desired period at a constant temperature of 300 K and constant pressure for the duration of 100 ns. The equations of motion were integrated with a 2 fs time step in the NPT ensemble. The SHAKE algorithm was applied to all hydrogen atoms, the van der Waals cutoff was 9 Å, and the temperature was maintained at 300 K, employing a Nose–Hoover thermostat with a relaxation time of 1 ps.

4.7.3. Molecular Docking. The energy-minimized hPgp model was used in the docking study. R and S enantiomers of TRZ-DHPMs were docked to the three drug-binding sites categorized by Ferreira et al.²⁴ as well as the ATP-binding site.³⁶ Compound structures were prepared with the Ligprep module of Schrödinger. All three binding site grids were calculated using the Glide module of Schrödinger,²⁵ and then the Glide XP docking was performed in all four binding sites individually.

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsomega.1c05839>.

Structures of all DHPMs prepared in this study; optimization of the CuAAC reaction and reaction conditions; analytical data of intermediates and other functionalized DHPMs prepared in this study; ¹H, ¹³C, and mass spectra for selected functionalized DHPMs; fluorescence intensity of calcein in Caco-2 VB and Caco-

2 cells; anticancer activities of all compounds; docking scores of selected DHPMs (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Anamik Shah – Center of Excellence, National Facility for Drug Discovery Complex, Department of Chemistry, Saurashtra University, Rajkot 360005, India; Astha, Saurashtra University Karmachari Cooperative Society, B/H Forensic Lab., Rajkot 360005, India; Email: anamik_shah@hotmail.com

Ashish Radadiya – Center of Excellence, National Facility for Drug Discovery Complex, Department of Chemistry, Saurashtra University, Rajkot 360005, India; School of Chemistry, Cardiff University, Cardiff CF10 3AT, UK; orcid.org/0000-0001-7348-1755; Email: radadiyaa@cardiff.ac.uk

Authors

Sabera Bijani – Center of Excellence, National Facility for Drug Discovery Complex, Department of Chemistry, Saurashtra University, Rajkot 360005, India; Department of Chemistry, Marwadi University, Rajkot 360003, India

Faraz Shaikh – Center of Excellence, National Facility for Drug Discovery Complex, Department of Chemistry, Saurashtra University, Rajkot 360005, India; Department of Computer and Information Science, University of Macau, Macau 999078, China; orcid.org/0000-0003-4664-2319

Sheefa Mirza – The Gujarat Cancer & Research Institute, Ahmedabad 380009, India; Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa

Shirley Weng In Siu – Department of Computer and Information Science, University of Macau, Macau 999078, China

Nayan Jain – Department of Life Sciences, School of Sciences, Gujarat University, Ahmedabad 380009, India

Rakesh Rawal – The Gujarat Cancer & Research Institute, Ahmedabad 380009, India; Department of Life Sciences, School of Sciences, Gujarat University, Ahmedabad 380009, India

Nigel G. J. Richards – School of Chemistry, Cardiff University, Cardiff CF10 3AT, UK; orcid.org/0000-0002-0375-0881

Complete contact information is available at: <https://pubs.acs.org/doi/10.1021/acsomega.1c05839>

Author Contributions

◆ S.B. and F.S. contributed equally to this work.

Author Contributions

S.B. performed chemical synthesis, F.S. performed all in silico studies guided by A.R., S.M. performed all biological assays guided by R.R., and N.G.J.R. read the manuscript drafts to correct errors in English grammar and spelling. The entire study was designed by A.R., and funding was acquired by A.S. The manuscript was written with contributions from all authors. All authors have given approval to the final version of the manuscript.

Funding

This work was supported by the Department of Biotechnology (DBT), New Delhi, India (grant BT/PR14653/BID/07/344/2010). Additional financial support for these studies was

provided by the University Grants Commission (UGC (SAP) DRS-II & DSA-I), DST (FIST-II), the National Facility for Drug Discovery Centre (DST-DPRP), the Council of Scientific & Industrial Research (02(0136)/13/EMR-II], and a Centre of Excellence grant funded by the Industries Commissionerate of Gujarat (A.S.)

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

F.S. thanks the DBT for a Junior Research Fellowship. A.R. thanks the University Grants Commission, New Delhi, India for a Basic Scientific Research Fellowship (F.7-157/2007 (BSR)).

ABBREVIATIONS

ATP, Adenosine triphosphate; ABC, ATP binding cassette; MDR, multidrug resistance; Pgp, P-glycoprotein; hPgp, human P-glycoprotein; MDR1, multidrug resistance 1; TM, transmembrane; DHPM, dihydropyrimidinone; CuAAC, copper-catalyzed alkyne-azide cycloaddition; DMF, dimethylformamide; PEG-400, polyethylene glycol 400; TRZ-DHPMs, triazole-conjugated DHPM derivatives; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide; IC₅₀, half maximal inhibition concentration; Caco-2 VB, vinblastine resistant Caco-2 cell lines that upregulate Pgp expression; SEM, standard error of the mean; TMD, transmembrane domain; NBD, nucleotide binding domain; MD, molecular dynamics

REFERENCES

- (1) Seelig, A. P-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers. *Front. Oncol.* **2020**, *10*, No. 576559.
- (2) Lai, J. I.; Tseng, Y. J.; Chen, M. H.; Huang, C. F.; Chang, P. M. Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics. *Front. Oncol.* **2020**, *10*, No. 561936.
- (3) D'Elia, P.; De Matteis, F.; Dragoni, S.; Shah, A.; Sgaragli, G.; Valoti, M. DP7, a novel dihydropyridine multidrug resistance reverter, shows only weak inhibitory activity on human CYP3A enzyme(s). *Eur. J. Pharmacol.* **2009**, *614*, 7–13.
- (4) Radadiya, A.; Khedkar, V.; Bavishi, A.; Vala, H.; Thakrar, S.; Bhavsar, D.; Shah, A.; Coutinho, E. Synthesis and 3D-QSAR study of 1,4-dihydropyridine derivatives as MDR cancer reverts. *Eur. J. Med. Chem.* **2014**, *74*, 375–387.
- (5) Lacotte, P.; Buisson, D. A.; Ambroise, Y. Synthesis, evaluation and absolute configuration assignment of novel dihydropyrimidin-2-ones as picomolar sodium iodide symporter inhibitors. *Eur. J. Med. Chem.* **2013**, *62*, 722–727.
- (6) da Silva, D. L.; Reis, F. S.; Muniz, D. R.; Ruiz, A. L.; de Carvalho, J. E.; Sabino, A. A.; Modolo, L. V.; de Fatima, A. Free radical scavenging and antiproliferative properties of Biginelli adducts. *Bioorg. Med. Chem.* **2012**, *20*, 2645–2650.
- (7) Strocchia, M.; Terracciano, S.; Chini, M. G.; Vassallo, A.; Vaccaro, M. C.; Dal Piaz, F.; Leone, A.; Riccio, R.; Bruno, I.; Bifulco, G. Targeting the Hsp90 C-terminal domain by the chemically accessible dihydropyrimidinone scaffold. *Chem. Commun.* **2015**, *51*, 3850–3853.
- (8) Treptow, T. G.; Figueiro, F.; Jandrey, E. H.; Battastini, A. M.; Salbego, C. G.; Hoppe, J. B.; Taborda, P. S.; Rosa, S. B.; Piovesan, L. A.; Montes D'Oca, C.; Russowsky, D.; Montes D'Oca, M. G. Novel hybrid DHPM-fatty acids: synthesis and activity against glioma cell growth in vitro. *Eur. J. Med. Chem.* **2015**, *95*, 552–562.
- (9) Dash, A. K.; Mukherjee, D.; Dhulap, A.; Haider, S.; Kumar, D. Green chemistry appended synthesis, metabolic stability and pharmacokinetic assessment of medicinally important chromene dihydropyrimidinones. *Bioorg. Med. Chem. Lett.* **2019**, *29*, No. 126750.
- (10) Sana, S.; Tokala, R.; Bajaj, D. M.; Nagesh, N.; Bokara, K. K.; Kiranmai, G.; Lakshmi, U. J.; Vadlamani, S.; Talla, V.; Shankaraiah, N. Design and synthesis of substituted dihydropyrimidinone derivatives as cytotoxic and tubulin polymerization inhibitors. *Bioorg. Chem.* **2019**, *93*, No. 103317.
- (11) Thirumurugan, P.; Matosiuk, D.; Jozwiak, K. Click chemistry for drug development and diverse chemical-biology applications. *Chem. Rev.* **2013**, *113*, 4905–4979.
- (12) Rani, A.; Singh, G.; Singh, A.; Maqbool, U.; Kaur, G.; Singh, J. CuAAC-enssembled 1,2,3-triazole-linked isosteres as pharmacophores in drug discovery: review. *RSC Adv.* **2020**, *10*, 5610–5635.
- (13) Sheehan, D. J.; Hitchcock, C. A.; Sibley, C. M. Current and emerging azole antifungal agents. *Clin Microbiol Rev* **1999**, *12*, 40–79.
- (14) Klix, M. B.; Verreet, J.-A.; Beyer, M. Comparison of the declining triazole sensitivity of *Gibberella zeae* and increased sensitivity achieved by advances in triazole fungicide development. *Crop Protect* **2007**, *26*, 683–690.
- (15) Xu, Z.; Zhao, S. J.; Liu, Y. 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. *Eur. J. Med. Chem.* **2019**, *183*, No. 111700.
- (16) Slavova, K. I.; Todorov, L. T.; Belskaya, N. P.; Palafox, M. A.; Kostova, I. P. Developments in the Application of 1,2,3-Triazoles in Cancer Treatment. *Recent Pat. Anti-Cancer Drug Discovery* **2020**, *15*, 92–112.
- (17) Hahn, D. W.; Byun, D. M.; Tae, J. Ring-Closing Metathesis Dimerizations of Enynes and Deprotections of Propargyl Ethers Mediated by Carbene Ruthenium Complexes. *Eur. J. Org. Chem.* **2005**, *2005*, 63–67.
- (18) Jain, S. L.; Singhal, S.; Sain, B. PEG-assisted solvent and catalyst free synthesis of 3,4-dihydropyrimidinones under mild reaction conditions. *Green Chem.* **2007**, *9*, 740–741.
- (19) Zilla, M. K.; Nayak, D.; Vishwakarma, R. A.; Sharma, P. R.; Goswami, A.; Ali, A. A convergent synthesis of alkyne-azide cycloaddition derivatives of 4- α , β -2-propyne podophyllotoxin depicting potent cytotoxic activity. *Eur. J. Med. Chem.* **2014**, *77*, 47–55.
- (20) Hung, C. C.; Chen, C. Y.; Wu, Y. C.; Huang, C. F.; Huang, Y. C.; Chen, Y. C.; Chang, C. S. Synthesis and biological evaluation of thiophenylbenzofuran derivatives as potential P-glycoprotein inhibitors. *Eur. J. Med. Chem.* **2020**, *201*, No. 112422.
- (21) Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. *Science* **2009**, *323*, 1718–1722.
- (22) Cavasotto, C. N.; Phatak, S. S. Homology modeling in drug discovery: current trends and applications. *Drug Discovery Today* **2009**, *14*, 676–683.
- (23) Alam, A.; Kowal, J.; Broude, E.; Roninson, I.; Locher, K. P. Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. *Science* **2019**, *363*, 753–756.
- (24) Ferreira, R. J.; Ferreira, M. J.; dos Santos, D. J. Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein. *J. Chem. Inf. Model.* **2013**, *53*, 1747–1760.
- (25) Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. *J. Med. Chem.* **2006**, *49*, 6177–6196.
- (26) Nosol, K.; Romane, K.; Irobalieva, R. N.; Alam, A.; Kowal, J.; Fujita, N.; Locher, K. P. Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1. *Proc. Natl. Acad. Sci. U. S. A.* **2020**, *117*, 26245–26253.

- (27) Cañeque, T.; Müller, S.; Rodriguez, R. Visualizing biologically active small molecules in cells using click chemistry. *Nat. Rev. Chem.* **2018**, *2*, 202–215.
- (28) Hans, R. H.; Guantai, E. M.; Lategan, C.; Smith, P. J.; Wan, B.; Franzblau, S. G.; Gut, J.; Rosenthal, P. J.; Chibale, K. Synthesis, antimalarial and antitubercular activity of acetylenic chalcones. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 942–944.
- (29) Sze, E. M. L.; Rao, W.; Koh, M. J.; Chan, P. W. H. Gold-catalyzed tandem intramolecular hetero-cyclization/Petasis-Ferrier rearrangement of 2-(prop-2-ynylloxy)benzaldehydes as an expedient route to benzo[b]oxepin-3(2H)-ones. *Chem. – Eur. J.* **2011**, *17*, 1437–1441.
- (30) Guantai, E. M.; Ncokazi, K.; Egan, T. J.; Gut, J.; Rosenthal, P. J.; Smith, P. J.; Chibale, K. Design, synthesis and *in vitro* antimalarial evaluation of triazole-linked chalcone and dienone hybrid compounds. *Bioorg. Med. Chem.* **2010**, *18*, 8243–8256.
- (31) Shah, K.; Mirza, S.; Desai, U.; Jain, N.; Rawal, R. Synergism of Curcumin and Cytarabine in the Down Regulation of Multi-Drug Resistance Genes in Acute Myeloid Leukemia. *Anti-Cancer Agents Med. Chem.* **2016**, *16*, 128–135.
- (32) Fiser, A.; Sali, A. Modeller: generation and refinement of homology-based protein structure models. *Methods Enzymol.* **2003**, *374*, 461–491.
- (33) Jin, M. S.; Oldham, M. L.; Zhang, Q.; Chen, J. Crystal structure of the multidrug transporter P-glycoprotein from *Caenorhabditis elegans*. *Nature* **2012**, *490*, 566–569.
- (34) Laskowski, R. A. PDBsum new things. *Nucleic Acids Res.* **2009**, *37*, D355–D359.
- (35) Lomize, M. A.; Pogozheva, I. D.; Joo, H.; Mosberg, H. I.; Lomize, A. L. OPM database and PPM web server: resources for positioning of proteins in membranes. *Nucleic Acids Res.* **2012**, *40*, D370–D376.
- (36) Kadioglu, O.; Saeed, M. E.; Valoti, M.; Frosini, M.; Sgaragli, G.; Efferth, T. Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: Functional and molecular docking analyses. *Biochem. Pharmacol.* **2016**, *104*, 42–51.

Recommended by ACS

Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure–Activity Relationship

Laura Figuerola-Asencio, Nadine Jagerovic, *et al.*

DECEMBER 02, 2022
ACS MEDICINAL CHEMISTRY LETTERS

READ 

Identification of Novel 2,4,5-Trisubstituted Pyrimidines as Potent Dual Inhibitors of Plasmodial *PfGSK3/PfPK6* with Activity against Blood Stage Parasites In Vitro

Kareem A. Galal, David H. Drewry, *et al.*

SEPTEMBER 27, 2022
JOURNAL OF MEDICINAL CHEMISTRY

READ 

Synthesis, Biological Evaluation, 2D-QSAR, and Molecular Simulation Studies of Dihydropyrimidinone Derivatives as Alkaline Phosphatase Inhibitors

Reem Altaf, Syed Aun Muhammad, *et al.*

FEBRUARY 18, 2022
ACS OMEGA

READ 

Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-*a*]pyridine Scaffold: SAR of t...

Stefano Sainas, Marco L. Lolli, *et al.*

SEPTEMBER 26, 2022
JOURNAL OF MEDICINAL CHEMISTRY

READ 

Get More Suggestions >